CRP: C-reactive protein; DBILI: direct bilirubin; ESR: erythrocyte sedimentation rate; GGT: gamma-glutamyl transferase; RABDO: rhabdomyolysis; RDW: red cell distribution width; SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase; -: no data.
Declarations
Author contributions
AA and NA: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. ET: Resources, Supervision. MT: Resources, Writing—review & editing. NGE: Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The study was approved by the Ethics Committee of Agia Sofia Children’s Hospital Reference Number 5893/2022, and complies with the Declaration of Helsinki.
Consent to participate
Informed consent to participate in the study was obtained from the participant’s guardians.
Consent to publication
Informed consent to publication was obtained from relevant participant guardians.
Availability of data and materials
The data of this manuscript could be available from the corresponding authors upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.Circulation. 2017;135:e927–99. [DOI] [PubMed]
Jone P, Tremoulet A, Choueiter N, Dominguez SR, Harahsheh AS, Mitani Y, et al.; American Heart Association Rheumatic Fever, Endocarditi, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association.Circulation. 2024;150:e481–500. [DOI] [PubMed]
Liu Y, Lin M, Wang J, Wu M. State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association.Pediatr Neonatol. 2018;59:543–52. [DOI] [PubMed]
Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children.J Am Soc Echocardiogr. 2011;24:60–74. [DOI] [PubMed]
Ghosh P, Katkar GD, Shimizu C, Kim J, Khandelwal S, Tremoulet AH, et al.; Pediatric Emergency Medicine Kawasaki Disease Research Group; Bocchini J, Das S, Burns JC, Sahoo D. An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease.Nat Commun. 2022;13:2687. [DOI] [PubMed] [PMC]
Rivas MN, Arditi M. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: Common Inflammatory Pathways of Two Distinct Diseases.Rheum Dis Clin North Am. 2023;49:647–59. [DOI] [PubMed] [PMC]
Yeo WS, Ng QX. Distinguishing between typical Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2.Med Hypotheses. 2020;144:110263. [DOI] [PubMed] [PMC]
Lee J, Kim BJ, Cho K, Rhim JW, Lee S, Jeong DC. Similarities and Differences between Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Shock Syndrome.Children (Basel). 2023;10:1527. [DOI] [PubMed] [PMC]
Ulu K, Çağlayan Ş, Coşkuner T, Vazgeçer EO, Öner T, Sözeri B. Differentiating Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Using Blood Composite Scores: Insights into Clinical Outcomes and Predictive Indices.Pediatr Cardiol. 2025;46:1390–9. [DOI] [PubMed] [PMC]
Wessels PA, Bingler MA. A comparison of Kawasaki Disease and multisystem inflammatory syndrome in children.Prog Pediatr Cardiol. 2022;65:101516. [DOI] [PubMed] [PMC]
Zhang Q, Xu B, Du J. Similarities and differences between multiple inflammatory syndrome in children associated with COVID-19 and Kawasaki disease: clinical presentations, diagnosis, and treatment.World J Pediatr. 2021;17:335–40. [DOI] [PubMed] [PMC]
Lee M, Liu Y, Tsai C, Hsu J, Wu J. Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki Disease.Front Pediatr. 2021;9:640118. [DOI] [PubMed] [PMC]
Tong T, Yao X, Lin Z, Tao Y, Xu J, Xu X, et al. Similarities and differences between MIS-C and KD: a systematic review and meta-analysis.Pediatr Rheumatol Online J. 2022;20:112. [DOI] [PubMed] [PMC]
Melgar M, Lee EH, Miller AD, Lim S, Brown CM, Yousaf AR, et al. Council of State and Territorial Epidemiologists/CDC Surveillance Case Definition for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection—United States.MMWR Recomm Rep. 2022;71:1–14. [DOI] [PubMed] [PMC]
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.Arthritis Rheumatol. 2021;73:e13–29. [DOI] [PubMed] [PMC]
Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.Pediatr Res. 2023;93:1499–508. [DOI] [PubMed] [PMC]
Marzano AV, Cassano N, Moltrasio C, Verdoni L, Genovese G, Vena GA. Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Review with an Emphasis on Mucocutaneous and Kawasaki Disease-Like Findings.Dermatology. 2022;238:35–43. [DOI] [PubMed] [PMC]
Jiang L, Tang K, Irfan O, Li X, Zhang E, Bhutta Z. Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents-a Live Systematic Review and Meta-analysis.Curr Pediatr Rep. 2022;10:19–30. [DOI] [PubMed] [PMC]
Giryes S, McGonagle D. Immune and non-immune mechanisms that determine vasculitis and coronary artery aneurysm topography in Kawasaki disease and MIS-C.Autoimmun Rev. 2023;22:103240. [DOI] [PubMed]
Gorelik M, Lee Y, Abe M, Andrews T, Davis L, Patterson J, et al. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis.Clin Exp Immunol. 2019;198:101–10. [DOI] [PubMed] [PMC]
Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.Autoimmun Rev. 2021;20:102763. [DOI] [PubMed]
Malcova H, Milota T, Strizova Z, Cebecauerova D, Striz I, Sediva A, et al. Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?Front Pharmacol. 2021;11:619273. [DOI] [PubMed] [PMC]
Maniscalco V, Abu-Rumeileh S, Mastrolia MV, Marrani E, Maccora I, Pagnini I, et al. The off-label use of anakinra in pediatric systemic autoinflammatory diseases.Ther Adv Musculoskelet Dis. 2020;12:1759720X20959575. [DOI] [PubMed] [PMC]
Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.Paediatr Drugs. 2020;22:645–52. [DOI] [PubMed] [PMC]
Rose DUD, Campi F, Maddaloni C, Ronci S, Caoci S, Savarese I, et al. Off-Label Use of Anakinra in Inflammatory Conditions in Neonates and Infants Up to 3 Months of Age: A Case Series and a Review of the Literature.Paediatr Drugs. 2025;27:293–305. [DOI] [PubMed] [PMC]
Sánchez-Manubens J, Gelman A, Franch N, Teodoro S, Palacios JR, Rudi N, et al. A child with resistant Kawasaki disease successfully treated with anakinra: a case report.BMC Pediatr. 2017;17:102. [DOI] [PubMed] [PMC]
Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.Pediatr Rheumatol Online J. 2014;12:26. [DOI] [PubMed] [PMC]
Walser M, Hermann M, Hufnagel M, Haas NA, Fischer M, Dalla-Pozza R, et al. Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease.Pediatr Infect Dis J. 2020;39:e310–3. [DOI] [PubMed]
Lind-Holst M, Hartling UB, Christensen AE. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.BMJ Case Rep. 2019;12:e229708. [DOI] [PubMed] [PMC]
Gambacorta A, Buonsenso D, Rosa GD, Lazzareschi I, Gatto A, Brancato F, et al. Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra.Front Pediatr. 2020;8:195. [DOI] [PubMed] [PMC]
Barbara Z, Ellenwood SP, Loe ED, Choi J, Ryan K, Joseph N. Kawasaki Disease Complicated by Salmonella oranienburg Coinfection.Case Rep Pediatr. 2021;2021:5584514. [DOI] [PubMed] [PMC]
Guillaume M, Reumaux H, Dubos F. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.Cardiol Young. 2018;28:739–42. [DOI] [PubMed]
Bossi G, Codazzi AC, Vinci F, Clerici E, Regalbuto C, Crapanzano C, et al. Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome.Children (Basel). 2022;9:672. [DOI] [PubMed] [PMC]
Blonz G, Lacroix S, Benbrik N, Warin-Fresse K, Masseau A, Trewick D, et al. Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra.J Clin Rheumatol. 2020;26:e42–3. [DOI] [PubMed]
Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series.Autoimmun Rev. 2018;17:768–74. [DOI] [PubMed]
Kone-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, et al. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.Arthritis Rheumatol. 2020;73:151–61. [DOI] [PubMed]
